Navigation Links
ChemoCentryx Announces 2011 Fourth Quarter and Full Year Financial Results
Date:3/30/2012

8 and the ChemR23 research program in 2011.

Research and development expenses for the fourth quarter 2011 were $5.4 million compared to $8.1 million for the same period in 2010. Research and development expenses for the year ended December 31, 2011 were $28.4 million compared to $33.5 million in 2010. The decrease was primarily due to the completion of the Phase II clinical trial for CCX354 in 2011.

General and administrative expenses for the fourth quarter of 2011 were $1.9 million and the same for the comparable period in 2010. General and administrative expenses for the year ended December 31, 2011 were $7.6 million compared to $7.3 million for 2010.

Cash, cash equivalents and investments totaled $96.1 million at December 31, 2011, compared to $82.8 million at December 31, 2010.

2012 Financial OutlookProjected 2012 year-end cash, cash equivalents and investments is expected to be at least $115.0 million.

About ChemoCentryxChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors.  Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's most advanced drug candidate, vercirnon (also known as Traficet-EN, CCX282, GSK1605786 or GSK'786), a specific CCR9 inhibitor, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Ohio , March 2, 2015  Akron Children,s ... Excellence™ (DICOE) by the American College of Radiology (ACR), ... and the second children,s hospital in ... designation.  "Earning recognition from the ACR ... perform at the highest level compared with national benchmarks," ...
(Date:3/2/2015)... , March 2, 2015  Kush Bottles, ... of child-resistant packaging solutions for the marijuana industry, ... Kovacevich , has been nominated for a 2015 ... Excellence in Entrepreneurship Award is designed to recognize ... individuals who, by their creativity and determination, have ...
(Date:3/2/2015)... -- Edison Investment Research, a leading ... full coverage of Abzena  Highlights of ... biotech analysts Christian Glennie and Dr ... offers a range of key services and technologies ... biological products. Antitope (immunogenicity testing, protein engineering, cell ...
Breaking Medicine Technology:Akron Children's designated ACR Diagnostic Imaging Center of Excellence 2Kush Bottles CEO, Nicholas Kovacevich, Nominated for 2015 "Excellence in Entrepreneurship Award" 2Edison Initiates Coverage on Abzena 2
(Date:3/2/2015)... Over the last five years the ultrasound ... to expand their geographic presence and achieve economies of ... $6.2 billion by 2019 at CAGR of 5.1% from ... and Canada and a major part of Europe are ... as Asia-Pacific including China and India, Latin America and ...
(Date:3/2/2015)... This year, the National Multiple Sclerosis Society’s annual ... for people across the country to unite, raise awareness, ... live their best lives. MS Awareness Week is a special ... join the Society’s vision of a world free of MS. ... of the central nervous system, interrupts the flow of information ...
(Date:3/2/2015)... Washington, DC (PRWEB) March 02, 2015 ... the publication of AIS’s Directory of Health Plans: ... comprehensive resource available on the U.S. health plan market, ... operating in the United States. , Available as ... “Executive Summary” of enrollment trends in quick-view tables and ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 A true renaissance ... leader of the 1960s cult rock band Khazad Doom, has ... his determination to persevere despite all odds. His motto throughout ... matter what situation or goal was before him. And that ... is now being passed on to a new generation. , ...
(Date:3/2/2015)... The Alliance for Bangladesh Worker Safety today announced ... serve as chief safety officer. In this role, he ... and guide remediation efforts in all factories from which ... the Alliance continues to bring world-class expertise to factory ... said Alliance Independent Chair Ellen Tauscher. “His role as ...
Breaking Medicine News(10 mins):Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 3Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2
... permanent damage, group warns , , SATURDAY, Jan. 17 ... you know how to protect yourself from frostbite? , "It ... the temperature falls below 20 degrees Fahrenheit and the wind ... Taizoon Baxamusa, spokesman for the American Academy of Orthopaedic Surgeons, ...
... Care Collaborative (SCC) will host Spiritual Care Summit ... Springs Resort in Walt Disney World®, FL. This ... the importance of spirituality in all aspects of ... dialogue among all professionals concerned with the spiritual ...
... for a chance to win up to $2,500 and ... enter Fred Hutchinson Cancer Research Center,s "Get Screened" video ... spotlight on the importance of colorectal-cancer screening - has ... the Hutchinson Center,s ongoing awareness campaign - "Your ...
... Plan, Asks Daschle to Investigate.WASHINGTON, Jan. 16 ... representatives to the Federal Interagency Autism Advisory Committee ... vaccine-autism research despite approval of the same studies ... by numerous autism organizations and requested by IACC,s ...
... might be sign of the condition, study says , , ... might one day help doctors detect some forms of ... the developmental disorder, Italian researchers say. , Scientists will ... this month, which looked at just 27 people ...
... numbers on the road, fewer older drivers died in crashes ... in years past, a new Insurance Institute for Highway Safety ... 21 percent during the period, reversing an upward trend, even ... percent. Compared with drivers ages 35-54, older drivers experienced much ...
Cached Medicine News:Health News:Hard, Cold Facts About Frostbite 2Health News:Spiritual Care Summit '09 Underscores Importance of Spirituality in All Aspects of Care 2Health News:Spiritual Care Summit '09 Underscores Importance of Spirituality in All Aspects of Care 3Health News:'Get Screened' Video Contest Deadline Extended to Jan. 30 2Health News:Federal Members of Advisory Committee Block Vaccine-Autism Research, Defy Wishes of Its Own Scientists, Autism Community, and Congress 2Health News:Saliva Test Could Indicate Autism 2Health News:Contrary to Earlier Predictions, Older Driver Fatal Crashes Trend Down 2Health News:Contrary to Earlier Predictions, Older Driver Fatal Crashes Trend Down 3
... Ophthalmic Products provide the ... free products for unparalleled ... cleaning of fine microsurgical ... material is highly absorbent, ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: